A panel of independent advisors to the FDA voted on Friday to recommend approval of an experimental peanut allergy drug from Aimmune Therapeutics. But concern about the risks of an allergic reaction to the therapy led the committee of mostly physicians to also recommend a safety plan to ensure that clinicians, patients, and their families understand the dangers that can come with treatment.
The vote was 7-2 in favor of recommending approval based on data that Brisbane, CA-based Aimmune (NASDAQ: AIMT) presented about its therapy, Palforzia. Asked whether to recommend approval of the therapy with additional safeguards, panelists voted… Read more »
UNDERWRITERS AND PARTNERS
